Market Cap
₹3,043 Cr.
P/E
29.96
Quick View
  • 1d
  • 1m
  • 6m
  • YTD
  • 1y
  • 3y
  • 5y
  • 10y
  • max

Company Timeline

Forensics
Other Income
Other Income is not affecting ratios of the company
Capex vs ROCE
ROCE of the company has decreased even without significant capex
Pledge
Promoters have not pledged a significant portion of their holding
Revenue Recognition
Chances of aggressive revenue recognition - Operating profit of company is not getting converted to cash and recievables rising faster than sales
Depreciation Effect
Depreciation accounting is not leading to increase in profits
Contingent Liabilities
Company does not have significant contingent liabilities
Retail Holding
Retail has been buying the stock which is usually a sign of exuberance
Share price
Share price has increased over last 10 years due to earnings
ROE
Net Profit Margin is responsible for ROE increase over last 10 years
Working Capital
Working Capital of the company seems to be under control
Debt
Company should not have issues servicing its debt
Promoter Holding
Promoter has not sold any shares in the last 90 days
Current vs Historic Valuation
Company is trading at a premium to 3 year historic valuations
ROE
Latest
13.83%
3yr Average
14.35%
5yr Average
9.23%
Net Profit Margin
Latest
8.53%
3yr Average
8.69%
5yr Average
5.59%
ROCE
Latest
16.9%
3yr Average
19.05%
5yr Average
13.14%
Debt to Equity
Latest
0.31
3yr Average
0.3
5yr Average
0.35
Market Share
0.24% (as of Jul 22)
Anti - Diabetes - Market Share
0.99% (as of Jul 22)
Anti-Infectives - Market Share
0.60% (as of Nov 21)
Blood Related - Market Share
0.02% (as of Jul 22)
Cardiovascular - Market Share
5.50% (as of Mar 23)
Carmicide - Market Share
49.90% (as of Mar 23)
Cyclopam - Market Share
0.36% (as of Nov 21)
Dermatology - Market Share
0.82% (as of Jul 22)
Gastro-Intestinal - Market Share
0.24% (as of Nov 21)
Gynecology - Market Share
88.70% (as of Mar 23)
Homide - Market Share
65.60% (as of Mar 23)
Karvol Plus - Market Share
63.20% (as of Mar 23)
Kidodent - Market Share
2.12% (as of Nov 21)
Ophthalmology - Market Share
0.30% (as of Nov 21)
Pain - Market Share
0.60% (as of Dec 22)
Pharmaceutical Sector - Market Share
52.20% (as of Mar 23)
Renolen - Market Share
1.50% (as of Nov 21)
Respiratory - Market Share
80% (as of Mar 23)
Rexidin M - Market Share
55.50% (as of Mar 21)
Rexidin Plus - Market Share
97.70% (as of Mar 23)
Sensodent-K - Market Share
47.80% (as of Mar 23)
Sensodent-KF - Market Share
60.30% (as of Mar 23)
Sensoform - Market Share
100% (as of Mar 23)
Snowdent - Market Share
23.05% (as of Nov 21)
Stomatological - Market Share
2.45% (as of Nov 21)
Urology - Market Share
0.58% (as of Jul 22)
Vitamin & Dietary Supplements - Market Share
Show more
Revenue mix

Product Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Therapeutic Area Wise Break-Up - Domestic

locked
Source
|
Latest
|
locked
Historic

Location Wise Break-Up -Formulation

locked
Source
|
Latest
|
locked
Historic

Location Wise Break-Up

locked
Source
|
Latest
|
locked
Historic
Show more
Operational Metrics

    Select a Metric
    • US DMF Filings (.)
    • Global DMFs filed (.)
    • Number of ANDA's Filed in USA (.)
    • Number of ANDA's Approved By USFDA (.)
    • Domestic Sales Growth - YoY (%)
    • R&D as a % of Total Sales (%)
    Peer Comparison
    Suppliers
    Company Filing
    Show Previous Years
    Discussions & Analysis